Command Palette

Search for a command to run...

Clinical Trials · NCT05394519

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
1,200
Start date
Feb 2023
Locations
179 sites, 13 countries
Primary endpoint
Relative change in body weight
View Semaglutide compound reference